Cargando…

sLAG-3 in non-small-cell lung cancer patients’ serum

BACKGROUND: Anti-programmed cell death-1/programmed cell death ligand-1 monoclonal antibodies have been widely used in non-small-cell lung cancer (NSCLC), but not every patient can get benefits from them. Whether other molecular markers can predict the results of programmed cell death-1/programmed c...

Descripción completa

Detalles Bibliográficos
Autores principales:	He, Yayi, Wang, Yan, Zhao, Sha, Zhao, Chao, Zhou, Caicun, Hirsch, Fred R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6097502/ https://www.ncbi.nlm.nih.gov/pubmed/30147330 http://dx.doi.org/10.2147/OTT.S164178

Ejemplares similares

The landscape of immune checkpoints expression in non-small cell lung cancer: a narrative review
por: Liu, Yu, et al.
Publicado: (2021)

Analysis of metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation
por: Chen, Yu, et al.
Publicado: (2021)

TIM-3, a promising target for cancer immunotherapy
por: He, Yayi, et al.
Publicado: (2018)

Major histocompatibility complex class II molecule in non-small cell lung cancer diagnosis, prognosis and treatment
por: Wang, Hao, et al.
Publicado: (2019)

PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes
por: He, Yayi, et al.
Publicado: (2017)

Risk factors for nicotine dependence in Chinese patients with lung cancer
por: Gu, Fen, et al.
Publicado: (2018)

Treatment of spine metastases in cancer: a review
por: Chen, Yu, et al.
Publicado: (2019)

Artificial intelligence-based analysis for immunohistochemistry staining of immune checkpoints to predict resected non-small cell lung cancer survival and relapse
por: Guo, Haoyue, et al.
Publicado: (2021)

KIR 2D (L1, L3, L4, S4) and KIR 3DL1 protein expression in non-small cell lung cancer
por: He, Yayi, et al.
Publicado: (2016)

Identification of sSIGLEC5 and sLAG3 as New Relapse Predictors in Lung Cancer
por: Montalbán-Hernández, Karla, et al.
Publicado: (2022)

YAP1 expression is associated with survival and immunosuppression in small cell lung cancer
por: Chen, Peixin, et al.
Publicado: (2023)

Immunotherapy as a treatment for small cell lung cancer: a case report and brief review
por: Wu, Yan, et al.
Publicado: (2020)

Combinational immunotherapy based on immune checkpoints inhibitors in small cell lung cancer: is this the beginning to reverse the refractory situation?
por: Guo, Haoyue, et al.
Publicado: (2020)

The Association between COX-2 Polymorphisms and Hematologic Toxicity in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Platinum-Based Chemotherapy
por: Zhou, Fei, et al.
Publicado: (2013)

Clinical Significance of Soluble LAG-3 (sLAG-3) in Patients With Cervical Cancer Determined via Enzyme-Linked Immunosorbent Assay With Monoclonal Antibodies
por: Li, Yang, et al.
Publicado: (2023)

Hepatic Metastases is Associated with Poor Efficacy of Erlotinib as 2(nd)/3(rd) Line Therapy in Patients with Lung Adenocarcinoma
por: He, Yayi, et al.
Publicado: (2016)

Update on lymphocyte-activation gene 3 (LAG-3) in cancers: from biological properties to clinical applications
por: Zhao, Lishu, et al.
Publicado: (2022)

Association of CD8 T cell apoptosis and EGFR mutation in non‐small lung cancer patients
por: Zhao, Chao, et al.
Publicado: (2020)

Serum Levels of the Cancer-Testis Antigen POTEE and Its Clinical Significance in Non-Small-Cell Lung Cancer
por: Wang, Qi, et al.
Publicado: (2015)

Lymphocyte‐activation gene‐3, an important immune checkpoint in cancer
por: He, Yayi, et al.
Publicado: (2016)

MiR-200c overexpression is associated with better efficacy of EGFR-TKIs in non-small cell lung cancer patients with EGFR wild-type
por: Li, Jiayu, et al.
Publicado: (2014)

Comparison of erlotinib and pemetrexed as second-/third-line treatment for lung adenocarcinoma patients with asymptomatic brain metastases
por: He, Yayi, et al.
Publicado: (2016)

Mechanisms of drugs-resistance in small cell lung cancer: DNA-related, RNA-related, apoptosis-related, drug accumulation and metabolism procedure
por: Chen, Peixin, et al.
Publicado: (2020)

CD137, an attractive candidate for the immunotherapy of lung cancer
por: Ye, Lingyun, et al.
Publicado: (2020)

Human leukocyte antigen class II-based immune risk model for recurrence evaluation in stage I–III small cell lung cancer
por: Chen, Peixin, et al.
Publicado: (2021)

Distinct patterns of somatic genomic alterations and mutational signatures in central and peripheral-type small-cell lung cancer
por: Wang, Lei, et al.
Publicado: (2021)

CD39: the potential target in small cell lung cancer
por: Chen, Shanhao, et al.
Publicado: (2020)

Seven-microRNA panel for lung adenocarcinoma early diagnosis in patients presenting with ground-glass nodules
por: He, Yayi, et al.
Publicado: (2017)

Long non-coding RNA UCA1 induces non-T790M acquired resistance to EGFR-TKIs by activating the AKT/mTOR pathway in EGFR-mutant non-small cell lung cancer
por: Cheng, Ningning, et al.
Publicado: (2015)

High feasibility of cytological specimens for detection of ROS1 fusion by reverse transcriptase PCR in Chinese patients with advanced non-small-cell lung cancer
por: Zhang, Limin, et al.
Publicado: (2019)

Non‐small cell lung cancer in China
por: Chen, Peixin, et al.
Publicado: (2022)

Clinicopathological and prognostic significance of regulatory T cells in patients with non-small cell lung cancer: A systematic review with meta-analysis
por: Zhao, Sha, et al.
Publicado: (2016)

Galectin-9-based immune risk score model helps to predict relapse in stage I–III small cell lung cancer
por: Chen, Peixin, et al.
Publicado: (2020)

Expression of PD-1 and PD-L1 on Tumor-Infiltrating Lymphocytes Predicts Prognosis in Patients with Small-Cell Lung Cancer
por: Sun, Chenglong, et al.
Publicado: (2020)

OX40 (CD134) and OX40 ligand, important immune checkpoints in cancer
por: Deng, Juan, et al.
Publicado: (2019)

Combination of Baseline and Variation of Prognostic Nutritional Index Enhances the Survival Predictive Value of Patients With Advanced Non-Small Cell Lung Cancer Treated With Programmed Cell Death Protein 1 Inhibitor
por: Fang, Qiyu, et al.
Publicado: (2022)

Clinicopathologic characteristics and outcomes of Chinese patients with non‐small‐cell lung cancer and BRAF mutation
por: Ding, Xi, et al.
Publicado: (2017)

The impact of EGFR exon 19 deletion subtypes on clinical outcomes in non-small cell lung cancer
por: Zhao, Chao, et al.
Publicado: (2020)

Ectopic expression of LAG‐3 in non–small‐cell lung cancer cells and its clinical significance
por: Ma, Chenglong, et al.
Publicado: (2020)

Cell Block as a Surrogate for Programmed Death-Ligand 1 Staining Testing in Patients of Non-Small Cell Lung Cancer
por: Dong, Zhengwei, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ggpcf5jpinq28vtornq7r7tb83